Skip to content
news
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results...
Oct 10, 2024
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize...
Oct 8, 2024
Lipocine to Host Virtual KOL Event on LPCN 2401 for...
Oct 2, 2024
Company
About Lipocine
Management
Board of Directors
Corporate Governance
Careers
Pipeline & Product
Pipeline
LPCN 1154 – Postpartum Depression
LPCN 2201 – Major Depressive Disorder
LPCN 2101 – Epilepsy
LPCN 2203 – Essential Tremor
LPCN 1148 – Management of Liver Cirrhosis
LPCN 2401 – Obesity Management
LPCN 1107 – Prevention of Preterm Birth
LPCN 1154 – Postpartum Depression
LPCN 2201 – Major Depressive Disorder
LPCN 2101 – Epilepsy
LPCN 2203 – Essential Tremor
LPCN 1148 – Management of Liver Cirrhosis
LPCN 2401 – Obesity Management
LPCN 1107 – Prevention of Preterm Birth
Product
TLANDO®
TLANDO®
Investors/Media
Press Releases
Presentations
Events
SEC Filings
Investor FAQ
Contact
Address & Inquiries
Business Development
Linkedin-in
Search
Contact
Contact
Corporate: 675 Arapeen Drive, Suite 202 Salt Lake City, Utah-84108
(t) 801.994.7383
(f) 801.994.7388
Directions:
From SLC International Airport
From Downtown SLC (Salt Palace Convention Center)
Careers:
View Career Opportunities
Send an email
Contact Us
Name
*
First
Last
*
Last
Phone
Email
*
Subject
*
Message
*
Send Message
If you are human, leave this field blank.
Innovating beyond
boundaries for patients